Filing Details

Accession Number:
0001567619-23-003311
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-17 17:04:54
Reporting Period:
2023-02-15
Accepted Time:
2023-02-17 17:04:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1740719 V Kathy Turner One Idexx Drive
Westbrook ME 04092
Senior Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-15 1,000 $79.54 8,380 No 4 A Direct
Common Stock Disposition 2023-02-15 1,000 $510.03 7,380 No 4 S Direct
Common Stock Acquisiton 2023-02-16 10 $79.54 7,390 No 4 M Direct
Common Stock Disposition 2023-02-16 10 $515.58 7,380 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2023-02-15 1,000 $0.00 1,000 $79.54
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2023-02-16 10 $0.00 10 $79.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,736 2025-02-13 No 4 M Direct
3,726 2025-02-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100 Indirect by spouse
Footnotes
  1. Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  2. The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
  3. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  4. Not applicable.